NCT00031915已完成2 期
Phase II Trial of Gleevec (Formerly Known as STI571) in Patients With Soft Tissue and Bone Sarcomas: A Multi-Disciplinary Trial of the North American Sarcoma Study Group of the Connective Tissue Oncology Society
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 试验地点
- 10
研究概览
简要总结
RATIONALE: Imatinib mesylate may stop the growth of tumor cells by blocking the enzymes necessary for cancer cell growth.
PURPOSE: Phase II trial to study the effectiveness of imatinib mesylate in treating patients who have metastatic or unresectable locally advanced soft tissue sarcoma or bone sarcoma.
详细描述
OBJECTIVES:
- Determine the efficacy of imatinib mesylate, as measured by response rate, in patients with metastatic or unresectable locally advanced soft tissue or bone sarcoma who have failed one or more prior treatment regimens.
- Determine the clinical and laboratory toxic effects of this drug in these patients.
OUTLINE: This is a multicenter study. Patients are stratified according to disease subtype.
Patients receive oral imatinib mesylate twice daily. Treatment continues for 1 year in the absence of disease progression or unacceptable toxicity.
PROJECTED ACCRUAL: A total of 60-120 patients (6-12 per stratum) will be accrued for this study.
研究设计
- 研究类型
- Interventional
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 10 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •DISEASE CHARACTERISTICS:
- •Histologically or cytologically confirmed metastatic or unresectable locally advanced (stage IV or recurrent) soft tissue or bone sarcoma
- •Eligible subtypes:
- •Ewing's family (e.g., primitive neuroectodermal tumor)
- •Osteosarcoma
- •Synovial sarcoma
- •Rhabdomyosarcoma (e.g., alveolar, embryonal, or pleomorphic)
- •Liposarcoma (all variants)
- •Malignant fibrous histiocytoma
- •Peripheral nerve sheath (e.g., malignant peripheral nerve sheath tumor, neurofibrosarcoma, or schwannoma)
- •Fibrosarcoma
- •Angiosarcoma (all variants)
- •Failed standard therapy with no available salvage regimens
- •Unidimensionally measurable target lesions by x-ray, CT scan, MRI, PET, or physical examination
- •Must be outside prior irradiation fields or have documented disease progression at least 6 weeks after completion of prior radiotherapy
- •PATIENT CHARACTERISTICS:
- •10 and over
- •Performance status:
- •Not specified
- •Life expectancy:
- •Not specified
- •Hematopoietic:
- •Not specified
- •Bilirubin no greater than 3 times upper limit of normal (ULN)
- •ALT and AST less than 2.5 times ULN
- •Creatinine less than 1.5 times ULN
- •Not pregnant or nursing
- •Negative pregnancy test
- •Fertile patients must use effective barrier contraception during and for at least 1 week after study participation for female patients and for at least 3 months after study participation for male patients
- •PRIOR CONCURRENT THERAPY:
- •Biologic therapy:
- •Not specified
- •Chemotherapy:
- •Not specified
- •Endocrine therapy:
- •No hormonal birth control
- •Radiotherapy:
- •See Disease Characteristics
- •At least 3 weeks since prior radiotherapy and recovered
- •Not specified
- •At least 28 days since any prior systemic therapy
排除标准
- 未提供
研究者
研究点 (10)
Loading locations...
相似试验
已完成
2 期
Imatinib Mesylate in Treating Patients With Recurrent Ewing's Family of Tumors or Desmoplastic Small Round-Cell TumorSarcomaNCT00062205City of Hope Medical Center40
已完成
2 期
S0338, Imatinib Mesylate and Capecitabine in Treating Women With Progressive Stage IV Breast CancerBreast CancerNCT00087152National Cancer Institute (NCI)27
已完成
2 期
Imatinib Mesylate in Treating Patients With Metastatic MelanomaSkin NeoplasmsMelanomaNCT00027586M.D. Anderson Cancer Center22
已完成
2 期
Imatinib Mesylate in Treating Patients With HIV-Related Kaposi's SarcomaSarcomaNCT00090987AIDS Malignancy Consortium30
终止
1 期
Imatinib Mesylate and Gemcitabine in Treating Patients With Locally Advanced, Metastatic, or Recurrent Pancreatic CancerPancreatic CancerNCT00281996Northwestern University19